B. Riley Initiates Coverage on Tandem Diabetes Care Inc(NASDAQ:TNDM). The shares have been rated Buy. The rating by B. Riley was issued on Sep 27, 2016.
Tandem Diabetes Care Inc (TNDM) made into the market gainers list on Fridays trading session with the shares advancing 3.93% or 0.29 points. Due to strong positive momentum, the stock ended at $7.66, which is also near the day’s high of $7.72. The stock began the session at $7.37 and the volume stood at 1,23,838 shares. The 52-week high of the shares is $12.48 and the 52 week low is $6.0421. The company has a current market capitalization of $235 M and it has 3,06,13,826 shares in outstanding.
Tandem Diabetes Care Inc(TNDM) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $22.98M. Analysts had an estimated revenue of $23.08M. Earnings per share were $-0.60. Analysts had estimated an EPS of $-0.65.
Several Insider Transactions has been reported to the SEC. On Aug 3, 2016, John F Sheridan (EVP, CHIEF OPERATING OFFICER) sold 15,000 shares at $6.52 per share price.Also, On Aug 4, 2015, Howard E Jr Greene (director) sold 20,000 shares at $12.70 per share price.
Tandem Diabetes Care Inc. is a medical device company engaged in designing developing and commercializing products for people with insulin-dependent diabetes. The Company’s products include t:slim Insulin Delivery System (t:slim) and t:flex Insulin Delivery System (t:flex). The t:slim consists of the t:slim pump its 300-unit disposable insulin cartridge and an infusion set. The t:flex consists of the t:flex pump its 480-unit disposable insulin cartridge and an infusion set. The Company’s technology platform features Micro-Delivery Technology a miniaturized pumping mechanism which draws insulin from a flexible bag within the pump’s cartridge rather than relying on a syringe and plunger mechanism.